127 related articles for article (PubMed ID: 6466571)
21. Study of erythrocyte mean corpuscular volume during cytotoxic therapy as a predictive parameter of the risk of secondary leukemia in Hodgkin's disease.
de Gramont A; Rioux E; Drolet Y; Delage JM
Cancer Treat Rep; 1984 Dec; 68(12):1467-70. PubMed ID: 6509452
[TBL] [Abstract][Full Text] [Related]
22. Therapy-induced preleukaemia in patients treated for Hodgkin's lymphoma: clinical and therapeutic relevance of sequential chromosome banding studies.
Gyger M; Forest L; Vuong TE; Perreault C; Lavallee R; Lacombe M; Boileau J; D'Angelo G
Br J Haematol; 1984 Sep; 58(1):61-9. PubMed ID: 6466572
[TBL] [Abstract][Full Text] [Related]
23. Incidence of post transplant myelodysplasia/acute leukemia in non-Hodgkin's lymphoma patients compared with Hodgkin's disease patients undergoing autologous transplantation following cyclophosphamide, carmustine, and etoposide (CBV).
Wheeler C; Khurshid A; Ibrahim J; Elias A; Mauch P; Ault K; Antin J
Leuk Lymphoma; 2001 Feb; 40(5-6):499-509. PubMed ID: 11426523
[TBL] [Abstract][Full Text] [Related]
24. [Acute non-lymphoblastic leukemia in patients treated for Hodgkin's disease. Analysis of 309 cases].
Marziano C; Vitali ML; Siragusa A; Vitale V
Minerva Med; 1983 Oct; 74(41):2453-8. PubMed ID: 6580555
[TBL] [Abstract][Full Text] [Related]
25. Secondary acute lymphoblastic leukaemia with 4:11 translocation following treatment for Hodgkin's disease: case report and review of the literature.
Lennard A; Jackson GH; Carey PJ; Bown N; Middleton P; Proctor SJ
Leukemia; 1991 Jul; 5(7):624-7. PubMed ID: 2072750
[TBL] [Abstract][Full Text] [Related]
26. Incidence of acute nonlymphocytic leukemia, preleukemia, and acute myeloproliferative syndrome up to 10 years after treatment of Hodgkin's disease.
Pedersen-Bjergaard J; Larsen SO
N Engl J Med; 1982 Oct; 307(16):965-71. PubMed ID: 7110299
[TBL] [Abstract][Full Text] [Related]
27. Hodgkin's disease and acute leukemia. Report of eight cases and review of the literature.
Rosner F; Grünwald H
Am J Med; 1975 Mar; 58(3):339-53. PubMed ID: 1090158
[TBL] [Abstract][Full Text] [Related]
28. Decreasing risk of leukemia with prolonged follow-up after chemotherapy and radiotherapy for Hodgkin's disease.
Blayney DW; Longo DL; Young RC; Greene MH; Hubbard SM; Postal MG; Duffey PL; DeVita VT
N Engl J Med; 1987 Mar; 316(12):710-4. PubMed ID: 3821809
[TBL] [Abstract][Full Text] [Related]
29. Risk of leukemia in patients treated for Hodgkin's disease.
Brusamolino E; Lazzarino M; Salvaneschi L; Canevari A; Morra E; Castelli G; Pagnucco G; Isernia P; Bernasconi C
Eur J Cancer Clin Oncol; 1982 Mar; 18(3):237-42. PubMed ID: 7201396
[TBL] [Abstract][Full Text] [Related]
30. Second malignancy in patients treated by Hodgkin's disease.
Baccarani M; Bosi A; Papa G
Cancer; 1980 Oct; 46(8):1735-40. PubMed ID: 6932997
[TBL] [Abstract][Full Text] [Related]
31. [Combined-modality therapy for 150 cases of early-stage Hodgkin's lymphoma].
Niu Y; Shi YK; He XH; Feng FY; Zhou LQ; Gu DZ
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):630-4. PubMed ID: 19102946
[TBL] [Abstract][Full Text] [Related]
32. Acute nonlymphocytic leukemia: a delayed complication of Hodgkin's disease therapy: analysis of 109 cases.
Cadman EC; Capizzi RL; Bertino JR
Cancer; 1977 Sep; 40(3):1280-96. PubMed ID: 409479
[TBL] [Abstract][Full Text] [Related]
33. Treatment of early clinically staged Hodgkin's disease with a combination of ABVD chemotherapy plus limited field radiotherapy.
Karmiris TD; Grigoriou E; Tsantekidou M; Spanou E; Mihalakeas H; Baltadakis J; Apostolidis J; Pagoni M; Karakasis D; Bakiri M; Mitsouli C; Harhalakis N; Nikiforakis E
Leuk Lymphoma; 2003 Sep; 44(9):1523-8. PubMed ID: 14565654
[TBL] [Abstract][Full Text] [Related]
34. Secondary acute non lymphoid leukemia in patients treated for non Hodgkin's lymphoma: no risk of therapy-related ANLL after PROVECIP schedule.
Cimino G; Anselmo AP; Cartoni C; Guglielmi C; Lo Coco F; Mancini M; Maurizi Enrici R; Papa G; Mandelli F
Tumori; 1987 Aug; 73(4):363-7. PubMed ID: 3310349
[TBL] [Abstract][Full Text] [Related]
35. Persistent abnormalities in red cell parameters following treatment of lymphoma.
Meytes D; Leshno D; Berkowicz M; Modan M; Ramot B
Leuk Lymphoma; 1994 Oct; 15(3-4):341-5. PubMed ID: 7866284
[TBL] [Abstract][Full Text] [Related]
36. Early-stage Hodgkin's disease: long-term results with radiotherapy alone or combined radiotherapy and chemotherapy.
Brusamolino E; Lazzarino M; Orlandi E; Canevari A; Morra E; Castelli G; Alessandrino EP; Pagnucco G; Astori C; Livraghi A
Ann Oncol; 1994; 5 Suppl 2():101-6. PubMed ID: 7515642
[TBL] [Abstract][Full Text] [Related]
37. Leukemia following Hodgkin's disease.
Kaldor JM; Day NE; Clarke EA; Van Leeuwen FE; Henry-Amar M; Fiorentino MV; Bell J; Pedersen D; Band P; Assouline D
N Engl J Med; 1990 Jan; 322(1):7-13. PubMed ID: 2403650
[TBL] [Abstract][Full Text] [Related]
38. Increased risk of secondary acute nonlymphocytic leukemia after extended-field radiation therapy combined with MOPP chemotherapy for Hodgkin's disease.
Andrieu JM; Ifrah N; Payen C; Fermanian J; Coscas Y; Flandrin G
J Clin Oncol; 1990 Jul; 8(7):1148-54. PubMed ID: 2193118
[TBL] [Abstract][Full Text] [Related]
39. The incidence of long-term side effects--in particular induced leukemias following treatment for Hodgkin's disease.
De Renzis C; Cellini N; Ausili Cefaro GP; Mantini G; Parisi S; Smaniotto D
Rays; 1986; 11(2):109-13. PubMed ID: 3602444
[No Abstract] [Full Text] [Related]
40. Leukemia risk following Hodgkin's disease: relation to cumulative dose of alkylating agents, treatment with teniposide combinations, number of episodes of chemotherapy, and bone marrow damage.
van Leeuwen FE; Chorus AM; van den Belt-Dusebout AW; Hagenbeek A; Noyon R; van Kerkhoff EH; Pinedo HM; Somers R
J Clin Oncol; 1994 May; 12(5):1063-73. PubMed ID: 8164031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
